Simon Chowdhury

Active 2011–2025

89
Papers
23,490
Citations
51
h-index
83
i10-index

Citations

Citations per year for Simon Chowdhury2000: 1 citations2001: 1 citations2003: 1 citations2006: 1 citations2012: 2 citations2013: 5 citations2014: 17 citations2015: 48 citations2016: 80 citations2017: 124 citations2018: 279 citations2019: 935 citations2020: 1,204 citations2021: 1,292 citations2022: 1,063 citations2023: 839 citations2024: 1,416 citations2025: 633 citations2026: 21 citations2002: no citations, so this year is not shown2004–2005: no citations, so these years are not shown2007–2011: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,357 citing papers, 23.6% of this breakdownUnited Kingdom: 864 citing papers, 8.6% of this breakdownChina: 749 citing papers, 7.5% of this breakdownItaly: 516 citing papers, 5.2% of this breakdownGermany: 511 citing papers, 5.1% of this breakdownCanada: 505 citing papers, 5.1% of this breakdownFrance: 479 citing papers, 4.8% of this breakdownJapan: 375 citing papers, 3.8% of this breakdownAustralia: 349 citing papers, 3.5% of this breakdownSpain: 345 citing papers, 3.4% of this breakdownSwitzerland: 302 citing papers, 3% of this breakdownNetherlands: 297 citing papers, 3% of this breakdown
0%23.6%Other 23.4%

Fields

  • Medicine74.9%
  • Biochemistry, Genetics and Molecular Biology17.3%
  • Immunology and Microbiology5%
  • Mathematics0.4%
  • Computer Science0.4%
  • Economics, Econometrics and Finance0.4%
  • Other1.6%

Topics

  • Prostate Cancer Treatment and Research15.6%
  • Prostate Cancer Diagnosis and Treatment8.9%
  • Cancer Immunotherapy and Biomarkers5.1%
  • Cancer Genomics and Diagnostics4.8%
  • Radiopharmaceutical Chemistry and Applications3.9%
  • Renal cell carcinoma treatment3.5%
  • Other58.2%

Coauthors

All papers

Open in search
  1. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Zielinski, Christopher J. Sweeney - New England Journal of Medicine 2019 cited by 1,593

  2. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 cited by 1,513

  3. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 3,031

  4. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 414

  5. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hoskin, J.F. Lester, Zafar Malik, Fiona McKinna, Neil McPhail, Julian Money‐Kyrle, Joe M. O’Sullivan, Omi Parikh, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Carys Thomas, John Wagstaff, James Wylie, Anjali Zarkar, Mahesh Parmar, Matthew R. Sydes - New England Journal of Medicine 2017 cited by 1,772

  6. Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 508

  7. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robert Hughes, Robert Laing, Fiona McKinna, Duncan B. McLaren, Joe M. O’Sullivan, Omi Parikh, C. Peedell, Andrew Protheroe, Angus Robinson, Narayanan Srihari, Rajaguru Srinivasan, John Staffurth, Santhanam Sundar, Shaun Tolan, David Tsang, John Wagstaff, Mahesh Parmar - The Lancet 2015 cited by 1,968

  8. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring aBRCA1orBRCA2Gene Alteration

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 678

  9. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,326

  10. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sai Jonnada, Sara Khaksar, J.F. Lester, Joe M. O’Sullivan, Omi Parikh, Ian Pedley, Delia Pudney, D.J. Sheehan, Narayanan Srihari, Anna Tran, Mahesh Parmar, Matthew R. Sydes - The Lancet 2018 cited by 1,262

  11. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Steve Hazell, Ashish Chandra, Lisa Pickering, Joanna Lynch, Sarah Rudman, Simon Chowdhury, Karen Harrison‐Phipps, Mary Varia, Catherine Horsfield, Alexander Polson, Gordon Stamp, Marie O’Donnell, William Drake, Peter Hill, David Hrouda, E J Mayer, Jonathan Olsburgh, G. Kooiman, Kevin C. O’Connor, Grant D. Stewart, Michael Aitchison, Maxine Tran, Nicos Fotiadis, Hema Verma, José I. López, J.F. Lester, Fiona J. E. Morgan, Malgorzata Kornaszewska, Richard Attanoos, Haydn Adams, Helen Davies, Dean A. Fennell, Jacqui Shaw, John Le Quesne, Apostolos Nakas, Sridhar Rathinam, William Monteiro, Hilary Marshall, Louise Nelson, Jonathan Bennett, Joan Riley, Lindsay Primrose, Luke Martinson, Girija Anand, Sajid Khan, M. Nicolson, Keith M. Kerr, Shirley Palmer, Hardy Remmen, J. Richard Miller, Keith Buchan, Mahendran Chetty, Lesley Gomersall, Sara Lock, Babu Naidu, Gerald Langman, Simon Trotter, Mary Bellamy, Hollie Bancroft, Amy Kerr, Salma Kadiri, Joanne Webb, Gary Middleton, Madava Djearaman, Yvonne Summers, Raffaele Califano, P. W. J. Taylor, Rajesh Shah, Piotr Krysiak, Kendadai Rammohan and 155 more - Cancer Cell 2018 cited by 585

  12. Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lisa Pickering, Martin Gore, Thomas B.K. Watkins, Sophia Ward, Aengus Stewart, Renzo G. DiNatale, Maria F. Becerra, Ed Reznik, James J. Hsieh, Todd Richmond, George F. Mayhew, Samantha M. Hill, Catherine D. McNally, Carol Jones, Heidi Rosenbaum, Stacey Stanislaw, Daniel L. Burgess, Nelson R. Alexander, Charles Swanton - Cell 2018 cited by 883

  13. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nik Matthews, Greg Elgar, Ben Phillimore, Marta Costa, Sharmin Begum, Sophia Ward, Max Salm, Stefan Boeing, Rosalie Fisher, Lavinia Spain, Carolina Navas, Eva Grönroos, Sebastijan Hobor, Sarkhara Sharma, Ismaeel Aurangzeb, Sharanpreet Lall, Alexander Polson, Mary Varia, Catherine Horsfield, Nicos Fotiadis, Lisa Pickering, Roland F. Schwarz, Bruno Silva, Javier Herrero, Nick M. Luscombe, Mariam Jamal‐Hanjani, Rachel Rosenthal, Nicolai J. Birkbak, Gareth A. Wilson, Orsolya Pipek, Dezső Ribli, Marcin Krzystanek, István Csabai, Zoltán Szállási, Martin Gore, Nicholas McGranahan, Peter Van Loo, Peter J. Campbell, James Larkin, Charles Swanton - Cell 2018 cited by 685

  14. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ian D. Davis, Ehtesham Abdi, Suzanne Allan, Patricia Bastick, Stephen Begbie, Robert Blum, Karen Briscoe, Daniel Brungs, Sean Bydder, Bala Renuka Chittajallu, Michelle R. Cronk, Katharine Cuff, Ian D. Davis, Anthony Dowling, Mark Frydenberg, M. C. George, Lisa G. Horvath, Elizabeth Hovey, Anthony M. Joshua, Narayan Karanth, Ganessan Kichenadasse, Laurence E. Krieger, Gavin Marx, Maitham Mathlum, Louise Nott, Zulfiquer Otty, Francis Parnis, David Pook, Shahneen Sandhu, Sanjeev Sewak, Amanda Gwendolyn Stevanovic, Martin R. Stockler, Aneta Suder, Hsiang Tan, Javier Torres, Simon Troon, Craig Underhill, Andrew Weickhardt, Robert Zielinski, Tahir Abbas, Ghadeer Anan, Chris Booth, H. E. A. Campbell, Kim Chi, Joseph L. Chin, E. Chouinard, Bryan Donnelly, Darrel Drachenberg, Amir Faghih, Antonio Finelli, Sebastién J. Hotte, Krista Noonan, Scott North, Mohammad Rassouli, Neil Reaume, Ricardo Rendon, Fred Saad, Evgeny Sadikov, Éric Vigneault, Paweł Zalewski, John McCaffrey, Ray McDermott, Patrick G. Morris, Miriam O’Connor, Paul Donnellan, Dearbhaile M. O’Donnell, Dearbhaile O'Donnell, Peter C.C. Fong, Alvin Tan, Simon Chowdhury and 13 more - The Lancet Oncology 2023 cited by 188

  15. Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Ross Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Dan George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raja Leibowitz, Christopher Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Amee Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Journal of Cancer 2023 cited by 157

  16. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mymoona Alzoueb, Omi Parikh, Angus Robinson, Isabel Syndikus, James Wylie, Anjali Zarkar, George Thalmann, Johann S de Bono, David P Dearnaley, Malcolm D Mason, Duncan Gilbert, Ruth E Langley, Robin Millman, David Matheson, Matthew R Sydes, Louise C Brown, Mahesh K B Parmar, Nicholas D James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, Dakshinamoorthy Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, Mohammed Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry Taylor, John Graham, Carla Perna, Lucinda Melcher, Warren Grant, Katherine Hyde, Ami Sabharwal, Uschi Hofmann, Robert Dealey and 73 more - The Lancet 2021 cited by 367

  17. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Andrew Wotherspoon, Steve Hazell, Myles Smith, D. Strauß, Andrew J. Hayes, Aspasia Soultati, Mark Stares, Lavinia Spain, Joanna Lynch, Nicos Fotiadis, Archana Fernando, Steve Hazell, Ashish Chandra, Lisa Pickering, Sarah Rudman, Simon Chowdhury, Charles Swanton, Mariam Jamal‐Hanjani, Selvaraju Veeriah, Seema Shafi, Justyna Czyzewska-Khan, Diana Johnson, Joanne Laycock, Leticia Bosshard‐Carter, Gerald Goh, Rachel Rosenthal, Pat Gorman, Nirupa Murugaesu, Robert E. Hynds, Gareth A. Wilson, Nicolai J. Birkbak, Thomas B.K. Watkins, Nicholas McGranahan, Stuart Horswell, Richard Mitter, Mickael Escudero, Aengus Stewart, Peter Van Loo, Andrew Rowan, Hang Xu, Samra Turajlic, Crispin T. Hiley, Christopher Abbosh, Jacki Goldman, Richard Stone, Tamara Denner, Nik Matthews, Greg Elgar, Sophia Ward, Jennifer Biggs, Marta Costa, Sharmin Begum, Ben Phillimore, Tim Chambers, Emma Nye, Sofia Graca, Maise Al Bakir, John A. Hartley, Helen L. Lowe, Javier Herrero, David Lawrence, Dahmane Oukrif, Nikolaos Panagiotopoulos, Shyam Kolvekar, Mary Falzon, Elaine Borg, Celia Simeon, Gemma Hector, Amy Smith, Marie Aranda and 152 more - Immunity 2017 cited by 430

  18. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2021 cited by 194

  19. Apalutamide and Overall Survival in Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 290

  20. Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David C. Wedge, Stuart Horswell, Tim Chambers, Kevin Litchfield, Hang Xu, Aengus Stewart, Réza Elaidi, Stéphane Oudard, Nicholas McGranahan, István Csabai, Martin Gore, P. Andrew Futreal, James Larkin, Andy G. Lynch, Zoltán Szállási, Charles Swanton, Peter J. Campbell - Cell 2018 cited by 564

  21. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 393

  22. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Urology 2023 cited by 97

  23. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Narayanan Srihari, Carys Thomas, Jacob Tanguay, John Wagstaff, Prantik Das, Emma Gray, Mymoona Alzouebi, Omi Parikh, Angus Robinson, Amir Montazeri, James Wylie, Anjali Zarkar, Richard Cathomas, Michael D. Brown, Yatin Jain, David P. Dearnaley, Malcolm D. Mason, Duncan C. Gilbert, Ruth E. Langley, Robin Millman, David Matheson, Matthew R. Sydes, Louise Brown, Mahesh Parmar, Nicholas D. James, Elin Jones, Katherine Hyde, Hilary Glen, Sarah Needleman, Ursula McGovern, Denise Sheehan, Sangeeta Paisey, Richard Shaffer, Mark Beresford, Zafar Malik, Anjali Zarkar, Emilio Porfiri, David Fackrell, Ling Lee, Thiagarajan Sreenivasan, Sue Brock, Simon Brown, Amit Bahl, Mike Smith-Howell, Cathryn Woodward, Mau-Don Phan, Danish Mazhar, Krishna Narahari, Jacob Tanguay, Fiona Douglas, Anil Kumar, Abdel Hamid, Azman Ibrahim, D. Muthukumar, Matthew Simms, Jane Worlding, Anna Tran, M. Kagzi, Prantik Das, Carmel Pezaro, Virgil Sivoglo, Benjamin Masters, Pek Keng-Koh, Caroline Manetta, Duncan B. McLaren, Nishi Gupta, Denise Sheehan, Stergios Boussios, Henry M. Taylor, John D. Graham and 80 more - The Lancet Oncology 2023 cited by 102

  24. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noel W. Clarke, Gedske Daugaard, Maria De Santis, Ignacio Durán, Rosalind A. Eeles, Eleni Efstathiou, Jason A. Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valérie Fonteyne, Nicola Fossati, Mark Frydenberg, Daniel J. George, Martin Gleave, Gwénaëlle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia S. Higano, Michael S. Hofman, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek‐Fossa, Robert J. Jones, Ravindran Kanesvaran, Pirkko‐Liisa Kellokumpu‐Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz‐Amit, Christopher J. Logothetis, Brandon A. Mahal, Fernando Cotait Maluf, Joaquı́n Mateo, David Matheson, Niven Mehra, Axel S. Merseburger, Alicia K. Morgans, Michael J. Morris, Hind M’rabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William Oh, Piet Ost, Joe M. O’Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M.C. Poon, Colin C. Pritchard, Danny Rabah, Dana E. Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard I. Scher, Nima Sharifi, Iwona Skoneczna, Howard R. Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki and 18 more - European Urology 2022 cited by 118